A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3002
Abstract: 3002Background: Hu5F9-G4 (5F9) is a humanized mAb that inhibits CD47, a “don’t eat me” signal for macrophages, and can enhance tumor cell phagocytosis and T-cell priming. Preclinically, 5F9 is acti... read more here.
Keywords: class first; human phase; phase pharmacokinetic; first human ... See more keywords